New vaccine trial aims to prevent breast cancer return

NCT ID NCT02826434

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a cancer vaccine (PVX-410) alone or with an immunotherapy drug (durvalumab) in 22 women with stage II or III triple negative breast cancer who have completed standard treatment. The goal is to see if the vaccine is safe and can boost the immune system to help prevent the cancer from coming back. Participants must have a specific genetic type (HLA-A2 positive).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33607, United States
Massachusetts general Hospital

Boston, Massachusetts, 02114, United States
New York University School of Medicine

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.